July 14, 2014
<p class="MsoNormal" style="line-height: 22.399999618530273px;">On the very last day of the 2014 legislative session, the New York Senate passed “The Compassionate Care Act” (S.1682-A, Savino) approving the <a href="http://www.usatoday.com/story/news/nation/2014/06/20/ny-set-to-legalize-medical-marijuana-/11033195/">legalization of medical marijuana</a>. The Assembly had previously passed a companion bill (A.6357-A, Gottfried). The Senate bill has been sent to Governor Cuomo for his signature. The governor endorsed the bill in the legislature, but as of July 4, 2014, has yet to sign it.</p>
<p class="MsoNormal" style="line-height: 22.399999618530273px;">New York medical marijuana proponents have been <a href="http://www.compassionatecareny.org">advocating</a> for the <a href="http://www.drugpolicy.org/new-york">availability of cannabis</a> for several years. Neighboring states Connecticut, New Jersey, and Vermont, and 18 other states and the District of Columbia currently allow medical marijuana. However, last minute compromise changes to the New York law will severely restrict access to medical cannabis. In fact, the limitations are so rigid that some might say the bill is a hallow shell, a sham, one designed to appear to allow medical marijuana yet really not. Regardless of how one feels about medical cannabis, to hype the public into believing that marijuana will be available for medical purposes and then establishing barriers to its accessibility that is a fraud. It would be unconscionable to raise the hopes of distressed patients, many suffering with chronic and painful conditions, only to see those hopes dashed.</p>
<p class="MsoNormal" style="line-height: 22.399999618530273px;"><strong style="color: #34405b; font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px;">The Alden March Bioethics Institute offers a Master of Science in Bioethics, a Doctorate of Professional Studies in Bioethics, and Graduate Certificates in Clinical Ethics and Clinical Ethics Consultation. For more information on AMBI's online graduate programs, please visit our <a style="text-decoration: underline; color: #000099;" href="/Academic/bioethics/index.cfm">website</a>.</strong></p>
April 10, 2014
by Craig Klugman, Ph.D.
After gay marriage, one of the most controversial issues in the United States today is the issue of marijuana.…
June 4, 2013
Craig Klugman, Ph.D.
Big brother is watching you. And calling you. And selling your medical information to a pharmaceutical corporation.
In the modern age of information as commodity, drugmakers buy database that tell them how much of what drug each doctor prescribes, which patients fill those prescriptions, and whether renewals are filled.…
August 14, 2011
A recent story in Nature highlights a few important concepts in the conduct of placebo-controlled trials. This story is about a very small placebo-controlled trial involving only 15 children who were stung by bark scorpions in Arizona. The trial’s goal was to demonstrate effectiveness of a new antivenom, Anascorp. The bark scorpion is the only […]
June 3, 2011
An interesting story recently from CBC highlights some of the difficulties with the topic of conflict of interest in medicine and biomedical research. Here’s a link to the story: CBC Tamiflu Probe Sparks Drug Policy Review “In the course of the CBC investigation, Zalac also reported that three of Canada’s most prominent flu experts — […]